Dexcom (DXCM) AI Stock Analysis

• Market Cap: $26.35B
• Dividend Yield: N/A
• Average Volume (3M): 4.75M
• Price to Earnings (P/E): 37.6
• Beta (1Y): 1.09
• Revenue Growth: 14.21%
• EPS Growth: 5.66%
• Country: US
• Employees: 10,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.61
• Shares Outstanding: 390,016,270
• 10 Day Avg. Volume: 4,099,029
• 30 Day Avg. Volume: 4,749,856
• PEG Ratio: 39.32
• Price to Book (P/B): 14.97
• Price to Sales (P/S): 7.80
• P/FCF Ratio: 49.89
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 5.98
• Enterprise Value/Gross Profit: 10.13
• Enterprise Value/Ebitda: 22.09
• 1Y Price Target: $85.38
• Price Target Upside: 26.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 23
• EPS Forecast (FY): 2.06
• Revenue Forecast (FY): $4.65B

• Rating: 79 Outperform
• Price Target: $75.00 ▲(11.00% Upside)

Dexcom's overall stock score reflects its strong financial performance and positive earnings call sentiment, which are the most significant factors. The stock's technical indicators suggest bullish momentum, but caution is advised due to potential overbought conditions. Valuation remains a concern with a high P/E ratio, and recent corporate events bolster long-term strategic positioning.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Dexcom's products, enhancing long-term financial stability and market position.

Expansion of CGM Access

Expanding CGM access broadens Dexcom's market reach, potentially increasing its customer base and recurring revenue streams.

Leadership Strengthening

Strengthening leadership with experienced figures supports innovation and strategic growth, vital for long-term competitiveness.

Negative Factors

Gross Margin Pressure

Decreasing margins can impact profitability, necessitating efficiency improvements to sustain financial health over time.

Quality and Deployment Issues

Deployment issues can affect brand reputation and customer retention, potentially hindering market expansion efforts.

CEO Medical Leave

Leadership changes can create uncertainty, impacting strategic decision-making and potentially affecting company performance.

Dexcom Business Overview & Revenue Model

Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

How the Company Makes Money

Dexcom generates revenue primarily through the sale of its continuous glucose monitoring systems and related supplies. The company's main revenue streams include the sale of CGM devices, sensors, transmitters, and software applications that enhance user experience and data management. Dexcom also partners with various healthcare providers, insurance companies, and diabetes education programs to promote its products and expand its market reach. These partnerships often lead to increased adoption of Dexcom’s technology among patients and healthcare professionals. Additionally, the company benefits from recurring revenue through the ongoing sales of sensors, which are required for continuous monitoring, thereby creating a stable revenue stream. Dexcom's strategic collaborations with pharmaceutical companies and technology firms further enhance its earnings potential by integrating its solutions with other diabetes management therapies.

Dexcom Financial Statement Overview

Summary

Dexcom demonstrates strong financial performance with consistent revenue growth and robust profitability. The income statement shows healthy margins, though there is room for improvement in gross profit margins. The balance sheet is stable with manageable leverage, and cash flow metrics indicate strong cash generation capabilities.

Income Statement

Dexcom's income statement shows strong revenue growth with a 5% increase in the TTM period. The company maintains healthy margins, with a gross profit margin of 59% and a net profit margin of 15.96%. EBIT and EBITDA margins are also robust at 13.75% and 23.12%, respectively. The consistent growth trajectory and profitability indicate a well-managed income statement, though slight declines in gross profit margin over the years suggest room for improvement.

Balance Sheet

Dexcom's balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.92, indicating manageable leverage. The return on equity is strong at 29.82%, showcasing effective utilization of shareholder funds. However, the equity ratio of 36.35% suggests a moderate reliance on debt financing. Overall, the balance sheet is solid but could benefit from a higher equity ratio to enhance financial stability.

Cash Flow

The cash flow statement highlights impressive free cash flow growth of 86.04% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio of 2.01 and free cash flow to net income ratio of 0.73 demonstrate efficient cash conversion. While the cash flow metrics are strong, maintaining this growth trajectory will be crucial for sustaining financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.52B	4.03B	3.62B	2.91B	2.45B	1.93B
Gross Profit	2.67B	2.44B	2.29B	1.88B	1.68B	1.28B
EBITDA	1.22B	945.70M	916.70M	565.30M	377.50M	376.80M
Net Income	720.70M	576.20M	541.50M	341.20M	216.90M	493.60M
Balance Sheet
Total Assets	7.50B	6.48B	6.26B	5.39B	4.93B	4.29B
Cash, Cash Equivalents and Short-Term Investments	3.32B	2.58B	2.72B	2.46B	2.73B	2.71B
Total Debt	2.52B	2.59B	2.59B	2.15B	2.16B	1.84B
Total Liabilities	4.77B	4.38B	4.20B	3.26B	2.89B	2.46B
Stockholders Equity	2.73B	2.10B	2.07B	2.13B	2.04B	1.83B
Cash Flow
Free Cash Flow	1.06B	630.70M	511.90M	304.70M	53.30M	276.60M
Operating Cash Flow	1.45B	989.50M	748.50M	669.50M	442.50M	475.60M
Investing Cash Flow	-74.30M	-207.50M	-507.20M	-521.50M	-216.10M	-1.02B
Financing Cash Flow	-165.80M	-734.80M	-318.60M	-552.50M	10.40M	912.10M

Dexcom Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 67.57
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXCM, the sentiment is Positive. The current price of 67.57 is above the 20-day moving average (MA) of 66.08, above the 50-day MA of 64.14, and below the 200-day MA of 73.96, indicating a neutral trend. The MACD of 1.06 indicates Negative momentum. The RSI at 59.79 is Neutral, neither overbought nor oversold. The STOCH value of 56.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DXCM.

Dexcom Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	79 Outperform	$26.35B	37.61	30.63%	―	14.21%	5.66%
EW	79 Outperform	$50.40B	36.97	13.59%	―	0.19%	65.58%
STE	77 Outperform	$25.07B	36.36	10.14%	0.94%	5.15%	60.30%
PODD	70 Outperform	$20.30B	83.75	19.68%	―	27.12%	-41.72%
SNN	69 Neutral	$14.00B	29.23	9.20%	2.28%	5.78%	61.52%
TNDM	61 Neutral	$1.52B	-7.33	-109.73%	―	17.87%	-57.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Dexcom Corporate Events

Dexcom Names Jacob Leach as Incoming Chief Executive

Dexcom’s board has confirmed that President and Chief Operating Officer Jacob S. Leach will assume the roles of President, Chief Executive Officer and director effective January 1, 2026, following the previously announced resignation of long-time CEO Kevin R. Sayer as of that date. On December 19, 2025, Leach agreed to an offer package that includes a $1,150,000 annual base salary, a target annual bonus equal to 150% of base pay, $7.5 million in time-vested restricted stock units over three years, and $7.5 million in performance stock units contingent on meeting compensation committee–set performance goals, while remaining eligible for existing executive severance and benefit plans; the board expects Sayer to return from medical leave around March 2026 to resume his role as board chairman, with Mark Foletta serving as interim chair in the meantime, signaling continuity in the company’s leadership transition and governance structure.

Dexcom Expands Board with New Appointment

On October 24, 2025, Dexcom‘s Board of Directors expanded to include Dr. Euan Ashley, a renowned researcher and clinician, who will serve on the Nominating and Governance Committee and the Technology Committee. This appointment, along with the planned addition of Jacob S. Leach in January 2026, is part of Dexcom’s strategic efforts to strengthen its leadership in medical technology and healthcare innovation, enhancing its capacity to advance metabolic health globally.